Download PDFPDF

Methotrexate: the gold standard without standardisation
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Methotrexate, the gold standard?
    • Cornelia F. Allaart, MD
    • Other Contributors:
      • Ben A.C. Dijkmans, VUMC Amsterdam, Tom W.J. Huizinga, LUMC Leiden, Pit J.S.M. Kerstens, JBI Amsterdam

    Dear editor,

    The editorial of colleagues Kay and Westhovens on the 3 E project about use of methotrexate makes some excellent points on the position of methotrexate in our daily practice, especially in the first 2 paragraphs.
    The fact that apparently methotrexate remains the initial preferred antirheumatic drug rests on perceived efficacy, an acceptable safety profile, and maybe predominantly on low...

    Show More
    Conflict of Interest:
    None declared.